Kezar Life Sciences, Inc.
$7.29
0%
2026-04-21 07:48:00
www.kezarlifesciences.com
NCM: KZR
Explore Kezar Life Sciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$53.74 M
Current Price
$7.29
52W High / Low
$7.55 / $3.53
Stock P/E
—
Book Value
$9.56
Dividend Yield
—
ROCE
-74.59%
ROE
-59.93%
Face Value
—
EPS
$-7.66
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
9
Beta
0.43
Debt / Equity
3.32
Current Ratio
11.52
Quick Ratio
11.52
Forward P/E
-2.76
Price / Sales
—
Enterprise Value
$-15.22 M
EV / EBITDA
0.3
EV / Revenue
—
Rating
Hold
Target Price
$6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Galmed Pharmaceuticals Ltd. | $0.75 | — | $4.81 M | — | -38.45% | -64.21% | $2.68 / $0.41 | $3.49 |
| 2. | Propanc Biopharma, Inc. | $0.12 | — | $2.33 M | — | -407.57% | -18.12% | $11 / $0.1 | $0.78 |
| 3. | Tonix Pharmaceuticals Holding Corp. | $14.34 | — | $184.59 M | — | -49.81% | -64.48% | $69.97 / $11.6 | $19.17 |
| 4. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
| 5. | Oruka Therapeutics, Inc. | $68.87 | — | $3.48 B | — | -25.79% | -24.69% | $70.5 / $8.36 | $9.63 |
| 6. | LeonaBio, Inc. | $9.38 | — | $83.23 M | — | -76.55% | -2.91% | $14.21 / $2.2 | $5.2 |
| 7. | Aura Biosciences, Inc. | $7.05 | — | $467.66 M | — | -74.67% | -73.52% | $7.48 / $4.34 | $2.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -8.33 M | -11.71 M | -14.6 M | -17.63 M | -21.57 M | — |
| Net Profit | -14.55 M | -11.23 M | -13.7 M | -16.56 M | -20.22 M | — |
| EPS in Rs | -1.97 | -1.52 | -1.86 | -2.25 | -2.74 | -2.78 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 7 M | 0 M |
| Operating Profit | -52.27 M | -89.14 M | -105.24 M | -71.16 M |
| Net Profit | -56.03 M | -83.74 M | -101.87 M | -68.24 M |
| EPS in Rs | -7.6 | -11.36 | -13.82 | -9.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 76.65 M | 144.68 M | 221.24 M | 299.57 M |
| Total Liabilities | 6.57 M | 27.77 M | 33.66 M | 29.7 M |
| Equity | 70.07 M | 116.92 M | 187.57 M | 269.87 M |
| Current Assets | 75.73 M | 137.49 M | 206.95 M | 285.72 M |
| Current Liabilities | 6.57 M | 20.33 M | 17.74 M | 11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -51.78 M | -74.21 M | -81.64 M | -58.85 M |
| Investing CF | 92.46 M | 80.43 M | 76.05 M | -91.39 M |
| Financing CF | -10.59 M | 0.1 M | 0.64 M | 127.86 M |
| Free CF | -51.78 M | -74.24 M | -83.45 M | -60.42 M |
| Capex | -0.01 M | -0.03 M | -1.81 M | -1.58 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 33.08% | 17.8% | -49.28% | — |
| Profit Margin % | — | — | -1455.29% | — |
| Operating Margin % | — | — | -1503.39% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -1417.91% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-10-30 | 1:0.1 |